Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2018

Open Access 01-12-2018 | NON-THEMATIC REVIEW

WNT5A as a therapeutic target in breast cancer

Authors: Chandra Prakash Prasad, Mansi Manchanda, Purusottam Mohapatra, Tommy Andersson

Published in: Cancer and Metastasis Reviews | Issue 4/2018

Login to get access

Abstract

Despite the clinical development of novel adjuvant and neoadjuvant chemotherapeutic drugs, metastatic breast cancer is one of the leading causes of cancer-related death among women. The present review focuses on the relevance, mechanisms, and therapeutic potential of targeting WNT5A as a future anti-metastatic treatment strategy for breast cancer patients by restoring WNT5A signaling as an innovative therapeutic option. WNT5A is an auto- and paracrine β-catenin-independent ligand that has been shown to induce tumor suppression as well as oncogenic signaling, depending upon cancer type. In breast cancer patients, WNT5A protein expression has been observed to be significantly reduced in between 45 and 75% of the cases and associated with early relapse and reduced disease-free survival. WNT5A triggers various downstream signaling pathways in breast cancer that primarily affect tumor cell migration and invasion. The accumulated in vitro results reveal that treatment of WNT5A-negative breast cancer cells with recombinant WNT5A caused different tumor-suppressive responses and in particular it impaired migration and invasion. The anti-migratory/invasive and anti-metastatic effects of reconstituting WNT5A signaling by the small WNT5A mimicking peptide Foxy5 form the basis for two successful clinical phase 1-studies aiming at determining safety and pharmacokinetics as well as defining dose-level for a subsequent phase 2-study. We conclude that re-installation of WNT5A signaling is an attractive and promising anti-metastatic therapeutic approach for future treatment of WNT5A-negative breast cancer patients.
Literature
1.
2.
Kumawat, K., & Gosens, R. (2016). WNT-5A: signaling and functions in health and disease. Cellular and Molecular Life Sciences, 73(3), 567–587.PubMedCrossRef
3.
Clark, C. C., Cohen, I., Eichstetter, I., Cannizzaro, L. A., McPherson, J. D., Wasmuth, J. J., & Iozzo, R. V. (1993). Molecular cloning of the human proto-oncogene Wnt-5A and mapping of the gene (WNT5A) to chromosome 3p14-p21. Genomics, 18(2), 249–260.PubMedCrossRef
4.
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003). Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature, 423(6938), 448–452.PubMedCrossRef
5.
6.
Port, F., & Basler, K. (2010). Wnt trafficking: new insights into Wnt maturation, secretion and spreading. Traffic, 11(10), 1265–1271.PubMedCrossRef
7.
Wong, G. T., Gavin, B. J., & McMahon, A. P. (1994). Differential transformation of mammary epithelial cells by Wnt genes. Molecular and Cellular Biology, 14(9), 6278–6286.PubMedPubMedCentralCrossRef
8.
Shimizu, H., Julius, M. A., Giarre, M., Zheng, Z., Brown, A. M., & Kitajewski, J. (1997). Transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell Growth & Differentiation, 8(12), 1349–1358.
9.
Jiang, W., Crossman, D. K., Mitchell, E. H., Sohn, P., Crowley, M. R., & Serra, R. (2013). WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells. PLoS One, 8(3), e58329.PubMedPubMedCentralCrossRef
10.
MacDonald, B. T., & He, X. (2012). Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. Cold Spring Harbor Perspectives in Biology, 4(12), a007880.PubMedPubMedCentralCrossRef
11.
Kühl, M., Sheldahl, L. C., Park, M., Miller, J. R., & Moon, R. T. (2000). The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends in Genetics, 16(7), 279–283.PubMedCrossRef
12.
Ishitani, T., Kishida, S., Hyodo-Miura, J., Ueno, N., Yasuda, J., Waterman, M., Shibuya, H., Moon, R. T., Ninomiya-Tsuji, J., & Matsumoto, K. (2003). The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Molecular and Cellular Biology, 23(1), 131–139.PubMedPubMedCentralCrossRef
13.
Oishi, I., Suzuki, H., Onishi, N., Takada, R., Kani, S., Ohkawara, B., Koshida, I., Suzuki, K., Yamada, G., Schwabe, G. C., Mundlos, S., Shibuya, H., Takada, S., & Minami, Y. (2003). The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes to Cells, 8(7), 645–654.PubMedCrossRef
14.
Yamaguchi, T. P., Bradley, A., McMahon, A. P., & Jones, S. (1999). A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development, 126(6), 1211–1223.PubMed
15.
Roarty, K., & Serra, R. (2007). Wnt5a is required for proper mammary gland development and TGF-β-mediated inhibition of ductal growth. Development, 134(21), 3929–3939.PubMedCrossRef
16.
Danielson, K. G., Pillarisetti, J., Cohen, I. R., Sholehvar, B., Huebner, K., Ng, L. J., Nicholls, J. M., Cheah, K. S. E., & Iozzo, R. V. (1995). Characterization of the complete genomic structure of the human WNT-5A gene, functional analysis of its promoter, chromosomal mapping, and expression in early human embryogenesis. The Journal of Biological Chemistry, 270(52), 31225–31234.PubMedCrossRef
17.
Leandersson, K., Riesbeck, K., & Andersson, T. (2006). Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. Nucleic Acids Research, 34(14), 3988–3999.PubMedPubMedCentralCrossRef
18.
19.
Dejmek, J., Leandersson, K., Manjer, J., Bjartell, A., Emdin, S. O., Vogel, W. F., et al. (2005). Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clinical Cancer Research, 11(2), 520–528.PubMed
20.
Sheehy, N. T., Cordes, K. R., White, M. P., Ivey, K. N., & Srivastava, D. (2010). The neural crest-enriched microRNA miR-452 regulates epithelial-mesenchymal signaling in the first pharyngeal arch. Development, 137(24), 4307–4316.PubMedPubMedCentralCrossRef
21.
Li, P., Cao, Y., Li, Y., Zhou, L., Liu, X., & Geng, M. (2014). Expression of Wnt-5a and β-catenin in primary hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 7(6), 3190–3195.PubMedPubMedCentral
22.
Jönsson, M., Dejmek, J., Bendahl, P.-O., & Andersson, T. (2002). Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Research, 62(2), 409–416.PubMed
23.
Sand-Dejmek, J., Ehrnström, R., Berglund, P., Andersson, T., & Ryden, L. (2013). The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women. PLoS One, 8(8), e70890.PubMedPubMedCentralCrossRef
24.
Borcherding, N., Kusner, D., Kolb, R., Xie, Q., Li, W., Yuan, F., Velez, G., Askeland, R., Weigel, R. J., & Zhang, W. (2015). Paracrine WNT5A signaling inhibits expansion of tumor-initiating cells. Cancer Research, 75(10), 1972–1982.PubMedPubMedCentralCrossRef
25.
Zhong, Z., Shan, M., Wang, J., Liu, T., Shi, Q., & Pang, D. (2016). Decreased WNT5A expression is a poor prognostic factor in triple-negative breast cancer. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 22, 1–7.CrossRef
26.
Huguet, E. L., Smith, K., Bicknell, R., & Harris, A. L. (1995). Regulation of Wnt5a mRNA expression in human mammary epithelial cells by cell shape, confluence, and hepatocyte growth factor. The Journal of Biological Chemistry, 270(21), 12851–12856.PubMedCrossRef
27.
Jonsson, M., & Andersson, T. (2001). Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. Journal of Cell Science, 114(11), 2043–2053.PubMed
28.
Dejmek, J., Dib, K., Jonsson, M., & Andersson, T. (2003). Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion. International Journal of Cancer, 103(3), 344–351.PubMedCrossRef
29.
Jauliac, S., Lopez-Rodriguez, C., Shaw, L. M., Brown, L. F., Rao, A., & Toker, A. (2002). The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nature Cell Biology, 4(7), 540–544.PubMedCrossRef
30.
Yiu, G. K., Kaunisto, A., Chin, Y. R., & Toker, A. (2011). NFAT promotes carcinoma invasive migration through glypican-6. Biochemical Journal, 440(1), 157–166.PubMedCrossRef
31.
Dejmek, J., Säfholm, A., Kamp Nielsen, C., Andersson, T., & Leandersson, K. (2006). Wnt-5a/Ca2+−induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells. Molecular and Cellular Biology, 26(16), 6024–6036.PubMedPubMedCentralCrossRef
32.
Kessenbrock, K., Smith, P., Steenbeek, S. C., Pervolarakis, N., Kumar, R., Minami, Y., Goga, A., Hinck, L., & Werb, Z. (2017). Diverse regulation of mammary epithelial growth and branching morphogenesis through noncanonical Wnt signaling. Proceedings of the National Academy of Sciences, 114(12), 3121–3126.CrossRef
33.
Roarty, K., Baxley, S. E., Crowley, M. R., Frost, A. R., & Serra, R. (2009). Loss of TGF-β or Wnt5a results in an increase in Wnt/β-catenin activity and redirects mammary tumour phenotype. Breast Cancer Research, 11(2), R19.PubMedCrossRefPubMedCentral
34.
Jang, G. B., Kim, J. Y., Cho, S. D., Park, K. S., Jung, J. Y., Lee, H. Y., Hong, I. S., & Nam, J. S. (2015). Blockade of Wnt/beta-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Science Reports, 5, 12465.CrossRef
35.
Yu, Q. C., Verheyen, E. M., & Zeng, Y. A. (2016). Mammary development and breast cancer: a Wnt perspective. Cancers (Basel), 8(7), 65.CrossRef
36.
Medrek, C., Landberg, G., Andersson, T., & Leandersson, K. (2009). Wnt-5a-CKIα signaling promotes β-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. The Journal of Biological Chemistry, 284(16), 10968–10979.PubMedPubMedCentralCrossRef
37.
Hansen, C., Howlin, J., Tengholm, A., Dyachok, O., Vogel, W. F., Nairn, A. C., Greengard, P., & Andersson, T. (2009). Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner. The Journal of Biological Chemistry, 284(40), 27533–27543.PubMedPubMedCentralCrossRef
38.
Prasad, C. P., Chaurasiya, S. K., Axelsson, L., & Andersson, T. (2013). WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Molecular Oncology, 7(5), 870–883.PubMedPubMedCentralCrossRef
39.
Louderbough, J. M., & Schroeder, J. A. (2011). Understanding the dual nature of CD44 in breast cancer progression. Molecular Cancer Research, 9(12), 1573–1586.PubMedCrossRef
40.
Xu, H., Wu, K., Tian, Y., Liu, Q., Han, N., Yuan, X., Zhang, L., Wu, G. S., & Wu, K. (2016). CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. International Journal of Oncology, 49(4), 1343–1350.PubMedPubMedCentralCrossRef
41.
Prasad, C. P., Chaurasiya, S. K., Guilmain, W., & Andersson, T. (2016). WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. Journal of Experimental & Clinical Cancer Research, 35(1), 144.CrossRef
42.
Dass, R. A., Sarshad, A. A., Carson, B. B., Feenstra, J. M., Kaur, A., Obrdlik, A., et al. (2016). Wnt5a signals through DVL1 to repress ribosomal DNA transcription by RNA polymerase I. PLoS Genetics, 12(8), e1006217.PubMedPubMedCentralCrossRef
43.
Laezza, C., d'Alessandro, A., Malfitano, A. M., & Bifulco, M. (2013). Anandamide inhibits the Wnt/beta-catenin signalling pathway in human breast cancer MDA MB 231 cells. European Journal of Cancer, 49(8), 2066–2067.PubMedCrossRef
44.
Xu, J., Prosperi, J. R., Choudhury, N., Olopade, O. I., & Goss, K. H. (2015). β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One, 10(2), e0117097.PubMedPubMedCentralCrossRef
45.
Shao, Y., Zheng, Q., Wang, W., Xin, N., Song, X., & Zhao, C. (2016). Biological functions of macrophage-derived Wnt5a, and its roles in human diseases. Oncotarget, 7(41), 67674–67684.PubMedPubMedCentralCrossRef
46.
Pukrop, T., Klemm, F., Hagemann, T., Gradl, D., Schulz, M., Siemes, S., Trumper, L., & Binder, C. (2006). Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proceedings of the National Academy of Sciences, 103(14), 5454–5459.CrossRef
47.
Nitzki, F., Zibat, A., König, S., Wijgerde, M., Rosenberger, A., Brembeck, F. H., Carstens, P. O., Frommhold, A., Uhmann, A., Klingler, S., Reifenberger, J., Pukrop, T., Aberger, F., Schulz-Schaeffer, W., & Hahn, H. (2010). Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Ptch-mutant mice via CaMKII. Cancer Research, 70(7), 2739–2748.PubMedCrossRef
48.
Zhu, Y., Tian, Y., Du, J., Hu, Z., Yang, L., Liu, J., et al. (2012). Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a-induced breast cancer cell migration. PLoS One, 7(5), e37823.PubMedPubMedCentralCrossRef
49.
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011). Regulation of cancer cell metabolism. Nature Reviews Cancer, 11(2), 85–95.PubMedCrossRef
50.
Sherwood, V. (2015). WNT signaling: an emerging mediator of cancer cell metabolism? Molecular Cell Biology, 35(1), 2–10.CrossRef
51.
Monga, S. P. (2011). Role of Wnt/beta-catenin signaling in liver metabolism and cancer. The International Journal of Biochemistry & Cell Biology, 43(7), 1021–1029.CrossRef
52.
Lee, S. Y., Jeon, H. M., Ju, M. K., Kim, C. H., Yoon, G., Han, S. I., Park, H. G., & Kang, H. S. (2012). Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Research, 72(14), 3607–3617.PubMedCrossRef
53.
Prasad, C. P., Sodergren, K., & Andersson, T. (2017). Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. Oncotarget, 8(42), 71471–71488.PubMedPubMedCentralCrossRef
54.
Sherwood, V., Chaurasiya, S. K., Ekström, E. J., Guilmain, W., Liu, Q., Koeck, T., et al. (2014). WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis, 35(4), 784–794.PubMedCrossRef
55.
Safholm, A., Leandersson, K., Dejmek, J., Nielsen, C. K., Villoutreix, B. O., & Andersson, T. (2006). A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. Journal of Biological Chemistry, 281(5), 2740–2749.PubMedCrossRef
56.
Safholm, A., Tuomela, J., Rosenkvist, J., Dejmek, J., Harkonen, P., & Andersson, T. (2008). The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clinical Cancer Research, 14(20), 6556–6563.PubMedCrossRef
57.
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436(7050), 518–524.PubMedPubMedCentralCrossRef
58.
Canesin, G., Evans-Axelsson, S., Hellsten, R., Krzyzanowska, A., Prasad, C. P., Bjartell, A., & Andersson, T. (2017). Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One, 12(9), e0184418.PubMedPubMedCentralCrossRef
Metadata
Title
WNT5A as a therapeutic target in breast cancer
Authors
Chandra Prakash Prasad
Mansi Manchanda
Purusottam Mohapatra
Tommy Andersson
Publication date
01-12-2018
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-018-9760-y

Other articles of this Issue 4/2018

Cancer and Metastasis Reviews 4/2018 Go to the issue

NON-THEMATIC REVIEW

MACC1—the first decade of a key metastasis molecule from gene discovery to clinical translation

NON-THEMATIC REVIEW

Cross-talk between lung cancer and bones results in neutrophils that promote tumor progression

OriginalPaper

Applications of Raman spectroscopy in cancer diagnosis

ReviewPaper

Cancers of the eye

OriginalPaper

Metabolic reprogramming of mitochondrial respiration in metastatic cancer

OriginalPaper

Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits